George S. Eisenbarth: insulin and type 1 diabetes - PubMed (original) (raw)
George S. Eisenbarth: insulin and type 1 diabetes
Alberto Pugliese et al. Diabetes Care. 2013 Jun.
No abstract available
Figures
An evocative rendering of the late George S. Eisenbarth. A pancreatic islet under immune attack against the backdrop of his model of the multiple stages in the natural history of T1D symbolizes the disease process he wanted to defeat.
Figure 1
The trimolecular complex—a key target for prevention. The fundamental work of Dr. Eisenbarth is illustrated in this schematic representation of the MHC class II molecule expressed on the surface on antigen-presenting cells (APC), the insulin peptide he proved to be required for diabetes development in the NOD mouse, and a conserved TCR α chain that diabetogenic CD4 T cells use to recognize the MHC-insulin peptide complex. The figure illustrates the concept that the peptide can bind to the MHC in multiple registers. Out of at least four registers, one is considered diabetogenic (middle panel) because it results in recognition of the peptide by insulin-specific autoreactive T cells expressing a conserved TCR α chain, and this is followed by their activation. In this register, peptide binding to the MHC is actually weak, and this is believed to impair the thymic deletion of the autoreactive cells when they first encounter this peptide in the thymus. The left panel models nondiabetogenic binding registers, which fail to result in the presentation of the insulin peptide and T-cell activation. The right panel shows that the use of small molecules could block this interaction and abolish the autoimmune response, with therapeutic benefit in the NOD mouse.
Similar articles
- Targeting the trimolecular complex: the pathway towards type 1 diabetes prevention.
Michels AW. Michels AW. Diabetes Technol Ther. 2013 Jun;15 Suppl 2(Suppl 2):S2-8-S2-12. doi: 10.1089/dia.2013.0114. Diabetes Technol Ther. 2013. PMID: 23786298 Free PMC article. - Delivering on George Eisenbarth's visionary pursuit of understanding pathogenesis and prevention of type 1 diabetes.
Insel RA. Insel RA. Diabetes Technol Ther. 2013 Jun;15 Suppl 2:S2-4-S2-7. doi: 10.1089/dia.2013.0106. Diabetes Technol Ther. 2013. PMID: 23786297 - George S. Eisenbarth, 1947-2012.
Atkinson MA. Atkinson MA. Diabetologia. 2013 Mar;56(3):435-8. doi: 10.1007/s00125-013-2833-0. Diabetologia. 2013. PMID: 23354126 No abstract available. - The 64-kDa beta cell membrane autoantigen and other target molecules of humoral autoimmunity in insulin-dependent diabetes mellitus.
Sigurdsson E, Baekkeskov S. Sigurdsson E, et al. Curr Top Microbiol Immunol. 1990;164:143-68. doi: 10.1007/978-3-642-75741-9_8. Curr Top Microbiol Immunol. 1990. PMID: 2073783 Review. No abstract available. - Autoantigens in type 1 diabetes mellitus.
Dotta F, Anastasi E, Tiberti C, Di Mario U. Dotta F, et al. J Endocrinol Invest. 1994 Jul-Aug;17(7):497-508. doi: 10.1007/BF03347744. J Endocrinol Invest. 1994. PMID: 7829824 Review. No abstract available.
Cited by
- Status of Diabetes Care: New Challenges, New Concepts, New Measures--Focusing on the Future!
Cefalu WT, Boulton AJ, Boulton AJ, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry R, Golden SH, Rich S, Reynolds L. Cefalu WT, et al. Diabetes Care. 2015 Jul;38(7):1177-80. doi: 10.2337/dc15-0875. Diabetes Care. 2015. PMID: 26312261 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
Personal name as subject
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical